Cantor Fitzgerald reissued their buy rating on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a research note issued to investors on Thursday, November 2nd. The brokerage currently has a $26.00 target price on the biotechnology company’s stock.
“Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS).”,” Cantor Fitzgerald’s analyst commented.
A number of other research firms also recently issued reports on NLNK. Robert W. Baird upgraded NewLink Genetics Corporation from a neutral rating to an outperform rating and raised their price target for the company from $8.00 to $22.00 in a research note on Friday, September 8th. Zacks Investment Research downgraded NewLink Genetics Corporation from a hold rating to a sell rating in a research note on Wednesday, July 12th. Jefferies Group LLC restated a hold rating and issued a $7.00 price target on shares of NewLink Genetics Corporation in a research note on Friday, July 14th. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a research note on Friday, October 13th. They issued a buy rating and a $22.00 price target for the company. Finally, ValuEngine downgraded NewLink Genetics Corporation from a sell rating to a strong sell rating in a research note on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $23.43.
Shares of NewLink Genetics Corporation (NLNK) traded down $0.54 during trading on Thursday, hitting $8.36. The company’s stock had a trading volume of 872,200 shares, compared to its average volume of 1,303,046. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17.
In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of the firm’s stock in a transaction dated Friday, October 6th. The shares were bought at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the purchase, the insider now owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.70% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in NewLink Genetics Corporation by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after acquiring an additional 51,013 shares during the last quarter. Columbus Circle Investors grew its position in NewLink Genetics Corporation by 72.5% during the 2nd quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock worth $4,349,000 after acquiring an additional 248,724 shares during the last quarter. Perceptive Advisors LLC bought a new stake in NewLink Genetics Corporation during the 3rd quarter worth $4,581,000. State Street Corp grew its position in NewLink Genetics Corporation by 1.2% during the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock worth $2,875,000 after acquiring an additional 4,630 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. grew its position in NewLink Genetics Corporation by 337.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after acquiring an additional 253,000 shares during the last quarter. Institutional investors own 45.31% of the company’s stock.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with our FREE daily email newsletter.